DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
IW-1701 is an investigational drug.
There have been 6 clinical trials for IW-1701. The most recent clinical trial was a Phase 1 trial, which was initiated on December 1st 2017.
The most common disease conditions in clinical trials are Anemia, Sickle Cell, Esophageal Achalasia, and [disabled in preview]. The leading clinical trial sponsors are Ironwood Pharmaceuticals, Inc. and [disabled in preview].
There are four US patents protecting this investigational drug and forty international patents.
Recent Clinical Trials for IW-1701
|A Trial to Evaluate the Effect of Itraconazole (ITZ), a CYP3A4 Inhibitor, on the Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator, Olinciguat (IW-1701), in Healthy Volunteers||Ironwood Pharmaceuticals, Inc.||Phase 1|
|A Trial to Study the Absorption, Metabolism, and Excretion of [14C]-Olinciguat in Healthy Male Volunteers||Ironwood Pharmaceuticals, Inc.||Phase 1|
|A Study of the Effect of IW-1701, a Stimulator of Soluble Guanylate Cyclase (sGC), on Patients With Sickle Cell Disease (SCD)||Ironwood Pharmaceuticals, Inc.||Phase 2|
Top disease conditions for IW-1701
Top clinical trial sponsors for IW-1701
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|IW-1701||Start Trial||sGC stimulators||Ironwood Pharmaceuticals, Inc. (Cambridge, MA)||Start Trial|
|IW-1701||Start Trial||sGC stimulators||Cyclerion Therapeutics, Inc. (Cambridge, MA)||Start Trial|
|IW-1701||Start Trial||sGC stimulators||IRONWOOD PHARMACEUTICALS, INC. (Cambridge, MA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|